Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
PT Phapros, Tbk is a leading Indonesian pharmaceutical company specializing in the production of generic and specialty drugs. With a strong domestic presence and a growing export market, particularly in Southeast Asia, the company leverages its extensive product portfolio and established distribution networks to drive revenue growth.
PT Phapros generates revenue primarily through the sale of generic pharmaceuticals, which benefit from lower production costs and high demand in emerging markets. The company has established pricing power due to its strong brand reputation and regulatory approvals, allowing it to maintain healthy margins despite competitive pressures.
Changes in government healthcare policies affecting drug pricing and reimbursement
New product approvals and launches, particularly in the generic segment
Expansion into new markets, especially in Southeast Asia
Fluctuations in raw material costs impacting gross margins
Regulatory changes that could impact drug approval processes and pricing
Technological disruptions in drug manufacturing and delivery
Intensifying competition from local and international generic manufacturers
Potential for price wars in the generic drug market
High debt-to-equity ratio (1.72) raises concerns about financial leverage
Liquidity risks if cash flow generation does not meet operational needs
moderate - The pharmaceutical sector is generally resilient during economic downturns, but demand can be influenced by consumer spending on healthcare.
Interest rates can affect the company's cost of capital and investment in R&D. Higher rates may compress margins if financing costs rise significantly.
minimal - The company is not heavily reliant on credit markets for operations, though higher debt levels could impact financial flexibility.
growth - Investors looking for exposure to emerging markets and healthcare innovation may find Phapros appealing.
moderate - The stock has shown significant price fluctuations, evidenced by a 33% decline over the past year.
